Mauritania vs Sao Tome and Principe: Number of HIV positive pregnant women receiving antiretrovirals
Mauritania
25
in 2011
Sao Tome and Principe
21
in 2011
Mauritania rank
36th
Sao Tome and Principe rank
37th
Number of HIV positive pregnant women receiving antiretrovirals over time
- Mauritania
- Sao Tome and Principe
How they compare
Mauritania currently reports 25 against 21 in Sao Tome and Principe, a difference of 4.
That makes Mauritania's figure about 1.2 times Sao Tome and Principe's.
Across all 5 years both countries report, Mauritania has been ahead every year.
Mauritania ranks 36th and Sao Tome and Principe ranks 37th of 38 countries.
Mauritania has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mauritania | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 33.75 | 13 | 20.75 | Mauritania |
| 2010s | 25 | 21 | 4 | Mauritania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher number of hiv positive pregnant women receiving antiretrovirals, Mauritania or Sao Tome and Principe?
- Mauritania, at 25 against 21 in Sao Tome and Principe as of 2011.
- What is the difference in number of hiv positive pregnant women receiving antiretrovirals between Mauritania and Sao Tome and Principe?
- 4, with Mauritania ahead.
- How many years of comparable data are there for Mauritania and Sao Tome and Principe?
- 5 years are reported by both, from 2005 to 2011.
- How do Mauritania and Sao Tome and Principe rank globally for number of hiv positive pregnant women receiving antiretrovirals?
- Mauritania ranks 36th and Sao Tome and Principe ranks 37th of 38 countries.
- Where does this data come from?
- http://data.unaids.org/pub/GlobalReport/2008/, published as Number of HIV positive pregnant women receiving antiretrovirals. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of HIV-infected pregnant women who received antiretrovirals during the last 12 months to reduce mother-to-child transmission. The purpose of this indicator is to assess progress in preventing vertical transmission of HIV.